Post-SSRI Sexual Dysfunction Across Epidemiology, Mechanisms, and Management: Scoping Review with ☸️SAIMSARA

Name: SAIMSARA Evidence Object mental::POST_SSRI_SEXUAL_DYSFUNCTION_SS
Creator: SAIMSARA
License: https://saimsara.com/license/

SAIMSARA

doi:10.62487/saimsara343e1f7e

SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

Post-SSRI Sexual Dysfunction Across Epidemiology, Mechanisms, and Management: Scoping Review with ☸️SAIMSARA

Mental & Neurological Health

Issue 4, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsara343e1f7e

Editorial note

• Last update: 2026-06-08 11:04:12

What is this paper about

Post-SSRI sexual dysfunction is emerging as a distinct and potentially enduring iatrogenic syndrome marked by erectile dysfunction, genital anesthesia, loss of libido, and profound effects on quality of life. This review maps the clinical evidence, mechanistic signals, treatment attempts, and major research gaps—showing what is already known, what remains uncertain, and why the full evidence landscape matters.

Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

☸️SAIMSARA v5.0

Abstract: To systematically scope and synthesize the breadth of evidence from human and animal studies on the epidemiology, clinical presentation, pathophysiological mechanisms, and management strategies for Post-SSRI Sexual Dysfunction (PSSD), in order to characterize the condition's core features, identify knowledge gaps, and provide a structured foundation for future research and clinical practice. The review uses 78 references and builds its evidence map from 335 original studies with 1231369 total participants/sample observations (topic-deduplicated ΣN). The evidence mapped here supports PSSD as a distinct, organically-grounded iatrogenic syndrome characterized by persistent erectile dysfunction, genital anesthesia, and loss of libido, with a quantified risk of approximately 1 in 216 patients treated with selective serotonin reuptake inhibitors (SSRIs) and ED reported in 88–93% of affected young men, with the mean IIEF score in the newer analysis consistent with severe ED. Convergent preclinical signals of enduring dopaminergic and transcriptomic dysregulation in reward and hypothalamic circuits lend biological plausibility to the clinical phenotype, while only 12% of patients recall pre-treatment counseling about sexual side effects, highlighting a clear informed-consent gap. Therapeutic evidence remains preliminary, with vortioxetine switching and select nutraceutical or multimodal approaches showing early promise. Overall, the literature indicates a recognizable syndrome lacking validated treatments, and the dominant future priority is a prospective, biomarker-enriched inception cohort capable of establishing incidence, mechanism, and reversibility.

Keywords: Post-SSRI Sexual Dysfunction; erectile dysfunction; genital anesthesia; sexual dysfunction; SSRI withdrawal; dopamine dysregulation; paroxetine; transcriptomic changes; quality of life; nutraceutical treatment

Review Stats

Final search date and database lock: 2026-05-30 23:20:52 CEST
Plan: Pro (expanded craft tokens; source: Semantic Scholar)
Source: Semantic Scholar
Total Abstracts/Papers: 4705
Downloaded Abstracts/Papers: 1000
Included original and non-original Abstracts/Papers (all): 524
Included original Abstracts/Papers (Vote counting by direction of effect): 335
Reference Index (links used in paper): 78
Total participants/sample observations (topic deduplicated ΣN): 1231369

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (78)

[1] Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence — https://doi.org/10.1017/s2045796024000441
[2] POST-FINASTERIDE SYNDROME AND POST-SSRI SEXUAL DYSFUNCTION: TWO CLINICAL CONDITIONS APPARENTLY DISTANT, BUT VERY CLOSE. — https://doi.org/10.1016/j.yfrne.2023.101114
[3] Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants — https://doi.org/10.1186/s12991-023-00447-0
[4] A clinical review of antidepressants, their sexual side-effects, post-SSRI sexual dysfunction, and serotonin syndrome. — https://doi.org/10.12968/bjon.2023.32.14.678
[5] Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? — https://doi.org/10.1007/s12020-018-1593-5
[6] Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors. — https://doi.org/10.1016/j.sxmr.2021.07.001
[7] Cutting the First Turf to Heal Post-SSRI Sexual Dysfunction: A Male Retrospective Cohort Study — https://doi.org/10.3390/medicines9090045
[8] PAROXETINE-INDUCED DOPAMINE DYSREGULATION: INSIGHTS INTO THE PATHOGENESIS OF POST-SSRI SEXUAL DYSFUNCTION (PSSD) — https://doi.org/10.1093/jsxmed/qdaf077.001

Unlock the full paper to view the complete Reference Index.